Intra-Cellular Therapies Inc. (ITCI) Financial Statements (2024 and earlier)

Company Profile

Business Address 430 EAST 29TH STREET
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments512,854538,708591,905664,713678,828129,295
Cash and cash equivalents142,25875,727148,615135,35877,235129,295
Short-term investments370,596462,981443,290529,355601,593 
Restricted cash and investments1,7501,7501,7501,7501,4001,400
Receivables95,96481,54575,18961,53846,97632,832
Inventory, net of allowances, customer advances and progress billings41,89528,34123,92023,59725,0227,893
Inventory41,89528,34123,92023,59725,0227,893
Other undisclosed current assets45,61055,75045,1938,15836,980676,922
Total current assets:698,073706,094737,957759,756789,206848,342
Noncurrent Assets
Operating lease, right-of-use asset13,78714,19914,82420,07320,47717,967
Property, plant and equipment1,6561,7791,9132,0842,1372,185
Other noncurrent assets868686868686
Total noncurrent assets:15,52916,06416,82322,24322,70020,238
TOTAL ASSETS:713,602722,158754,780781,999811,906868,580
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities29,35625,09733,39156,51947,51928,292
Employee-related liabilities21,15018,38516,643
Accounts payable7,7338,44110,39514,21910,74911,649
Accrued liabilities21,62316,65622,99621,15018,385 
Other undisclosed current liabilities62,72454,49049,84520,89123,11530,782
Total current liabilities:92,08079,58783,23677,41070,63459,074
Noncurrent Liabilities
Long-term debt and lease obligation:    19,16719,07516,756
Liabilities, other than long-term debt14,43214,96115,474   
Operating lease, liability14,43214,96115,47419,16719,07516,756
Other undisclosed noncurrent liabilities    (19,167)(19,075)(16,756)
Total noncurrent liabilities:14,43214,96115,47419,16719,07516,756
Total liabilities:106,51294,54898,71096,57789,70975,830
Equity
Equity, attributable to parent607,090627,610656,070685,422722,197792,750
Common stock10109999
Additional paid in capital2,173,6712,151,8372,137,7372,124,3692,106,9422,089,418
Accumulated other comprehensive loss(2,268)(2,698)(4,190)(5,496)(4,802)(3,328)
Accumulated deficit(1,564,323)(1,521,539)(1,477,486)(1,433,460)(1,379,952)(1,293,349)
Total equity:607,090627,610656,070685,422722,197792,750
TOTAL LIABILITIES AND EQUITY:713,602722,158754,780781,999811,906868,580

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues110,79295,30687,86971,87055,57934,996
Gross profit:110,79295,30687,86971,87055,57934,996
Operating expenses(157,971)(143,698)(135,281)(127,499)(143,502)(107,658)
Operating loss:(47,179)(48,392)(47,412)(55,629)(87,923)(72,662)
Nonoperating income
(Investment Income, Nonoperating)
4,5304,3493,3862,1221,320548
Loss from continuing operations before income taxes:(42,649)(44,043)(44,026)(53,507)(86,603)(72,114)
Income tax expense(135)(10) (1) (5)
Loss from continuing operations:(42,784)(44,053)(44,026)(53,508)(86,603)(72,119)
Loss before gain (loss) on sale of properties:(53,508)(86,603)(72,119)
Net loss available to common stockholders, diluted:(42,784)(44,053)(44,026)(53,508)(86,603)(72,119)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(42,784)(44,053)(44,026)(53,508)(86,603)(72,119)
Other comprehensive income (loss)4301,4921,306(694)(1,474)(2,964)
Comprehensive loss, net of tax, attributable to parent:(42,354)(42,561)(42,720)(54,202)(88,077)(75,083)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: